Hartaj Singh
Stock Analyst at Oppenheimer
(1.77)
# 3,204
Out of 5,182 analysts
106
Total ratings
47.87%
Success rate
-6.69%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $20.98 | +76.36% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $744.44 | +20.90% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $127.75 | -2.15% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $426.01 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $57.18 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $566.99 | +5.82% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $48.70 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $4.01 | +149.38% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.73 | +3,368.21% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.95 | +361.54% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.17 | +3,318.80% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $12.96 | +69.75% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.79 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $4.88 | +13,219.67% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $22.12 | +35.62% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $20.98
Upside: +76.36%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $744.44
Upside: +20.90%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $127.75
Upside: -2.15%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $426.01
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $57.18
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $566.99
Upside: +5.82%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $48.70
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $4.01
Upside: +149.38%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.73
Upside: +3,368.21%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.95
Upside: +361.54%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.17
Upside: +3,318.80%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $12.96
Upside: +69.75%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $0.79
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $4.88
Upside: +13,219.67%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $22.12
Upside: +35.62%